+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study



Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study



Journal of Neonatal-Perinatal Medicine 9(3): 251-259



Inhaled nitric oxide (iNO) is the standard therapy for infants with persistent pulmonary hypertension of the newborn (PPHN). Recently, sildenafil has been evaluated as an alternative or adjunctive pulmonary vasodilator. To assess the effectiveness of adding sildenafil as an early adjunctive therapy together with iNO when treating newborns with PPHN and/or hypoxemic respiratory failure. This is a randomized placebo trial on newborns with gestational age > 34 weeks, postnatal age < 48 hours, and diagnosed with PPHN (oxygen index (OI) ≥ 20). Newborns were randomized to two groups: Group A- received oral sildenafil and iNO, and group B- received placebo and iNO. Initial and follow up echocardiography were performed over 14 days period. A total of 24 newborns were recruited; 13 of them received sildenafil in addition to iNO and 11 received iNO and placebo. The most common causes of PPHN were meconium aspiration syndrome, pneumonia, and RDS. At the starting point, OI was marginally higher in the intervention group without statistical significance (29 vs 28). There were no differences between the two groups regarding surfactant administration, incidence of pneumothoraces, and the underlying causes of PPHN. Sildenafil or placebo treatment started within 12 hours after starting iNO (8 vs 6 hours). Early use of oral sildenafil next to iNO in cases of PPHN was tolerated well by newborns and it did not show significant adverse effects. Further studies with a larger sample size is needed to assess its effecacy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057703256

Download citation: RISBibTeXText

PMID: 27589542

DOI: 10.3233/npm-16161


Related references

Five year neurodevelopmental outcome of infants with persistent pulmonary hypertension of the newborn treated with inhaled nitric oxide. Pediatric Research 47(4 Part 2): 310A, 2000

Long term neurodevelopmental outcome of infants with persistent pulmonary hypertension of the newborn treated with inhaled nitric oxide. Pediatric Research 49(4 Part 2): 338A, 2001

Effect of nebulised iloprost combined with inhaled nitric oxide and oral sildenafil on lung transplant patients. Therapeutic efficacy in pulmonary hypertension during surgery. Revista Espanola de Anestesiologia Y Reanimacion 59(3): 142-149, 2014

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 105(20): 2398-2403, May 21, 2002

Effect of inhaled nitric oxide therapy and weaning from INO in very low birthweight infants with severe persistent pulmonary hypertension of the newborn. Pediatric Research 49(4 Part 2): 418A, 2001

Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. European Journal of Pediatrics 164(10): 626-629, 2005

Effect of inhaled nitric oxide on endothelin-1 and cyclic guanosine 5'-monophosphate plasma concentrations in newborn infants with persistent pulmonary hypertension. Journal of Pediatrics 130(4): 603-611, 1997

Effect of initial nitric oxide concentration on outcome in infants with persistent pulmonary hypertension of the newborn. Biology of the Neonate 75(4): 215-224, 1999

Effect of Initial Nitric Oxide Concentration on Outcome in Infants with Persistent Pulmonary Hypertension of the Newborn. Neonatology 75(4): 215-224, 1999

Persistent pulmonary hypertension in premature and newborn infants: selective pulmonary vasodilation with inhaled nitric oxide (iNO). Zeitschrift für Geburtshilfe und Neonatologie 202(1): 25-29, 1998

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. American Journal of Cardiology 90(6): 677-680, 2002

Severe neonatal pulmonary hypertension secondary to antenatal maternal diclofenac ingestion reversed by inhaled nitric oxide and oral sildenafil. Annals of Saudi Medicine 27(6): 448-449, 2007

Prophylactic treatment of oral sildenafil citrate for pulmonary hypertension in an infant treated with inhaled nitric oxide after open-heart surgery. Kyobu Geka. Japanese Journal of Thoracic Surgery 58(13): 1136-1139, 2005

Inhaled nitric oxide and methemoglobinemia in term infants with persistent pulmonary hypertension of the newborn. Pediatric Research 45(4 Part 2): 222A, 1999

Outcome of neonates with persistent pulmonary hypertension of the newborn treated with inhaled nitric oxide. Journal of the Medical Association of Thailand 85(7): 800-807, 2002